CROX:NASDAQCrocs, Inc. Analysis
Data as of 2026-09-18 - not real-time
$120.91
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The moving-average structure behind Crocs, Inc. is neutral at $120.91, with no clear ordering between short and long averages. Over a rolling month the price has lost 9.9%. RSI sits at 51.5, which reads as neutral, and MACD momentum is bullish. Price has been bracketed by support at $108.54 and resistance at $125.92.
Multiples put this in fair territory at a P/E of 10.7. Consensus targets land 14.3% above where the shares trade now. Revenue is growing at 2.6% on a 14.6% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 38.3%, a beta of 0.96 and a maximum drawdown of 24.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 5 out of 10.
Multiples put this in fair territory at a P/E of 10.7. Consensus targets land 14.3% above where the shares trade now. Revenue is growing at 2.6% on a 14.6% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 38.3%, a beta of 0.96 and a maximum drawdown of 24.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 5 out of 10.
Top Market Events
Yahoo Finance1monCrocs CROX Is Up 6.7% After Earnings Beat And Larger Buybacks Authorization Has The Bull Case...Updated Sep 4, 2026 0 BROOMFIELD, Colo., Sept. 4, 2026 /PRNewswire/ -- Crocs, Inc. NASDAQ: CROX , a world leader in...Here is how Crocs CROX and Superior Group SGC have performed compared to their sector so far this year.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- Trading above the 200-day average of 104.76
- MACD momentum is positive
- 30-day price change of -9.9%
Medium Term
1–3 yearsPositive
Model confidence: 5/10
Key Factors
- Trading above the 200-day average of 104.76
- Analyst targets imply +14.3% versus the current price
- MACD momentum is positive
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Analyst targets imply +14.3% versus the current price
- P/E ratio of 10.7
- Return on equity of 42.3%
Key Metrics & Analysis
Financial Health
Revenue Growth2.60%
Profit Margin14.64%
P/E Ratio10.7
ROE42.30%
ROA11.99%
Debt/Equity121.99
P/B Ratio4.2
Op. Cash Flow$762.6M
Free Cash Flow$533.9M
Technical Analysis
TrendNeutral
RSI51.5
Support$108.54
Resistance$125.92
MA 20$117.62
MA 50$126.85
MA 200$104.76
MACDBullish
VolumeIncreasing
Fear & Greed Index94.13
Valuation
Fair Value$120.95
Target Price$138.25
Upside/Downside14.35%
GradeFair
TypeBlend
Risk Assessment
Beta0.96
Volatility38.29%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.